NAFLD: A multisystem disease
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries that is predicted to become also the most frequent indication for liver transplantation by 2030. Over the last decade, it has been shown that the clinical burden of NAFLD is not only confined to liver-related morbidity and mortality, but there is now growing evidence that NAFLD is a multisystem disease, affecting extra-hepatic organs and regulatory pathways. For example, NAFLD increases risk of type 2 diabetes mellitus (T2DM), cardiovascular (CVD) and cardiac diseases, and chronic kidney disease (CKD). Although the primary liver pathology in NAFLD affects hepatic structure and function to cause morbidity and mortality from cirrhosis, liver failure and hepatocellular carcinoma, the majority of deaths among NAFLD patients are attributable to CVD. This narrative review focuses on the rapidly expanding body of clinical evidence that supports the concept of NAFLD as a multisystem disease. The review discusses the factors involved in the progression of liver disease in NAFLD and the factors linking NAFLD with other extra-hepatic chronic diseases, such as T2DM, CVD, cardiac diseases and CKD. The review will not discuss NAFLD treatments as these are discussed elsewhere in this issue of the Journal. For this review, PubMed was searched for articles using the keywords "non-alcoholic fatty liver disease" or "fatty liver" combined with "diabetes", "cardiovascular (or cardiac) disease", "cardiovascular mortality" or "chronic kidney disease" between 1990 and 2014. Articles published in languages other than English were excluded.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ZHOU, Y. J., LI, Y. Y., NIE, Y. Q., HUANG, C. M., & CAO, C. Y. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 78
RetractedDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 3×
“With regard to biopsy-diagnosed NAFLD (as shown in Table 2) [23,24,88–90,97,98], some retrospective studies with reasonably long follow-up have clearly shown that all-cause, CVD and liver-related mortality were significantly higher in NAFLD patients than in matched control populations.”
BackgroundAssessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 1×
“The use of direct measurements of GFR should be encouraged as the creatinine-based equations are not accurate in estimating GFR, especially for patients with severe obesity or cirrhosis [141].”
BackgroundThe Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · cited 3×
“2005 [98] Retrospective cohort”
BackgroundEndoplasmic reticulum stress and the inflammatory basis of metabolic disease
Hotamisligil, G. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.034 · Cited by 2,802
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Research works printed but not linked: 1
- Konfortion, 2014, Time and deprivation trends in incidence of primary liver cancer subtypes in England, J Eval Clin Pract, 20, 498, 10.1111/jep.12188 · doi:10.1111/jep.12188
Cited by
Items 101–130 of 130
Mantovani, A., Sani, E., Fassio, A., Colecchia, A., Viapiana, O., Gatti, D., Idolazzi, L., Rossini, M., Salvagno, G., Lippi, G., et al. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.001 · Cited by 68
Rezaei, S., Sasani, M. R., Akhlaghi, M., & Kohanmoo, A. (2020) · British Journal of Nutrition · doi:10.1017/s0007114520000318 · Cited by 63
“Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide (1) .”
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
“According to predictions, it will become the first cause by 2030.(5) Lifestyle intervention is currently the mainstay treatment for NAFLD.”
BackgroundBlood‐Bile Barrier: Morphology, Regulation, and Pathophysiology
Pradhan-Sundd, T., & Monga, S. P. (2019) · Gene Expression · doi:10.3727/105221619x15469715711907 · Cited by 54
Non-alcoholic fatty liver disease and its association with depression in Korean General Population
Jung, J. Y., Park, S. K., Oh, C.-M., Chung, P.-W., & Ryoo, J.-H. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e199 · Cited by 51
Liver macrophages: development, dynamics, and functions
Nusse, Y., & Kubes, P. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01298-3 · Cited by 50
Vilar-Gomez, E., Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., Bhanpuri, N. H., McKenzie, A. L., Campbell, W. W., McCarter, J. P., Phinney, S. D., Volek, J. S., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023597 · Cited by 50
“Non-alcoholic fatty liver disease (NAFLD) is an important cause of chronic liver disease 87 (CLD), hepatocellular carcinoma (HCC) and liver transplant worldwide, and is associated with 88 increased risk of heart disease, diabetes, chronic kidney disease and malignancies[1-4].”
BackgroundReview of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1894127 · Cited by 47
“[2,3], and it is not only a liver-related disorder, but clinical evidence describes it as a multisystem disorder [4,5].”
BackgroundThe future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
“The complex pathophysiology involves multiple features, such as metabolic disturbances, lipotoxicity, insulin resistance, chronic inflammation, fibrosis, intestinal function and the gut microbiome [57], and is closely associated with obesity, type 2 diabetes and the metabolic syndrome [58].”
BackgroundObeticholic acid: towards first approval for NASH
Eslam, M., Alvani, R., & Shiha, G. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32963-0 · Cited by 43
Sharma, D., Gotlieb, N., Farkouh, M. E., Patel, K., Xu, W., & Bhat, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022576 · Cited by 36
Scorletti, E., Creasy, K. T., Vujkovic, M., Vell, M., Zandvakili, I., Rader, D. J., Schneider, K. M., & Schneider, C. V. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001726 · Cited by 33
A decade of liver organoids: Advances in disease modeling
Liu, Y., Sheng, J.-Y., Yang, C.-F., Ding, J., & Chan, Y.-S. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0428 · Cited by 30
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01431-2 · Cited by 27
“NAFLD is considered as being related to metabolic syndrome, and is highly associated with peripheral and hepatic insulin resistance, obesity, T2D, dyslipidemia and CV disease [37].”
BackgroundAlKhatry, M., Rapaka, B., Maselli, D. B., Abboud, D. M., Brunaldi, V. O., Mahmoud, T., Ghazi, R., Abdul Razzak, F., Gala, K., Joudah, I., et al. (2023) · Endoscopy · doi:10.1055/a-2117-6274 · Cited by 23
“Introduction Nonalcoholic fatty liver disease (NAFLD) continues to rise as a common cause of chronic liver disease globally [1].”
BackgroundGe, X., Wang, X., Yan, Y., Zhang, L., Yu, C., Lu, J., Xu, X., Gao, J., Liu, M., Jiang, T., et al. (2023) · Liver International · doi:10.1111/liv.15588 · Cited by 23
“Two aims were focused on (1) to evaluate the combined effect of physical activity, sedentary behaviour, and genetic factors on the NAFLD risk, and (2) to assess the degree to which adherence to a healthy behavioural pattern modified the impact of genetic susceptibility on the NAFLD risk.”
BackgroundMethodHepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor
Wang, Z., Miu, K.-K., Zhang, X., Wan, A. T.-Y., Lu, G., Cheung, H.-H., Lee, H.-M., Kong, A. P.-S., Chan, J. C.-N., & Chan, W.-Y. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100179 · Cited by 22
“JHEP Reports 2020 NAFLD is recognised as the predominant form of chronic liver disease associated with metabolic disorders, such as T2DM, obesity, and hyperlipidaemia.(26) NAFLD was caused by the inhability of insulin to suppress hepatic glucose production in obese people with diabetes, with NAFLD further promoting di…”
BackgroundDe Roza, M. A., Lamba, M., Goh, G. B.-B., Lum, J. H.-M., Cheah, M. C.-C., & Ngu, J. H. J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i43.7563 · Cited by 21
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020) · Diabetic Medicine · doi:10.1111/dme.14356 · Cited by 21
Jiang, N., Zhang, S., Chu, J., Yang, N., & Lu, M. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24973 · Cited by 20
Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α
Yu, L., Wang, H., Han, X., Liu, H., Zhu, D., Feng, W., Wu, J., & Bi, Y. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0555 · Cited by 19
Qiao, W., Li, J., Luo, L., Peng, W., Wang, X., Jin, R., & Li, J. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117436 · Cited by 16
Beyazal Polat, H., Beyazal, M., Arpa, M., Kızılkaya, B., Ayaz, T., Gündoğdu, Ö. L., Konur, K., Polat, Z., Beyazal Çeliker, F., & Atasoy, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103513 · Cited by 13
“These processes collectively increase the risk of developing or worsening T2DM [12,28,29].”
Hooshmand Gharabagh, L., Shargh, A., Mohammad Hosseini Azar, M. R., & Esmaeili, A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102279 · Cited by 13
Hunter, H., de Gracia Hahn, D., Duret, A., Im, Y. R., Cheah, Q., Dong, J., Fairey, M., Hjalmarsson, C., Li, A., Lim, H. K., et al. (2020) · eLife · doi:10.7554/elife.56573 · Cited by 12
Karimi, M., Akhgarjand, C., Houjaghani, H., Nejad, M. M., Sohrabpour, A. A., Poustchi, H., Mohammadi, H., Chamari, M., & Imani, H. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.01.007 · Cited by 12
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Billeter, A. T., Reiners, B., Seide, S. E., Probst, P., Kalkum, E., Rupp, C., & Müller-Stich, B. P. (2022) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-21-5 · Cited by 12
Xu, X., Dong, Y., Liu, J., Zhang, P., Yang, W., & Dai, L. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s480574 · Cited by 9
Jin, L., Cui, Y., Zhang, Q., Xiong, Y., Zheng, X., Ye, J., Zhang, A., Xiao, Z., Zhuang, Z., Liang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114053 · Cited by 1
Metadata
- Authors
- Byrne, C. D., & Targher, G.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 62
- Issue
- 1
- Pages
- S47-S64
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2162382402
- Cited by
- 3,042
- References
- 151
- FWCI
- 99.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.